Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma

• Published in: Journal of Hematology & Oncology 2012, Vol.5
• Main Authors: Kim, Yu Ri, Kim, Jin Seok, Min, Yoo Hong, Yoon, Dok Hyun, Shin, Ho-Jin, Mun, Yeung-Chul, Park, Yong, Do, Young Rok, Jeong, Seong Hyun, Park, Joon Seong, Oh, Sung Yong, Lee, Suee, Park, Eun Kyung, Jang, Joung-Soon, Lee, Won-Sik, Lee, Hwe-Won, Eom, HyeonSeok, Ahn, Jae-sook, Jeong, Jae-Heon, Baek, Sun Kyung, Kim, Seok Jin, Kim, Won Seog, Suh, Cheolwon
• Format: Report
• Language: English
• Subjects: Adrenal glands; Anthracyclines; Cancer; Care and treatment; Chemotherapy; Corticosteroids; Cyclophosphamide; Development and progression; Health aspects; Lymphomas; Non-Hodgkin's lymphomas; Prednisone; Prognosis
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/1756-8722-5-49

Background The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. Methods Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. Results Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P < 0.001). Conclusions Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value. Keywords: Primary adrenal lymphoma, Diffuse large B-cell lymphoma, Prognostic factor, R-CHOP